Showing 1-10 of about 16 articles.
BiPar Sciences
PARIS and SOUTH SAN FRANCISCO, Calif., July 17, 2009 (GLOBE NEWSWIRE) -- Sanofi-aventis (EURONEXT:SAN) (NYSE:SNY) and its wholly owned subsidiary, BiPar Sciences, today announced the initiation of the ...
BiPar Sciences
PARIS and BRISBANE, Calif., May 31, 2009 (GLOBE NEWSWIRE) -- Sanofi-aventis (EURONEXT:SAN) (NYSE:SNY) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2 ...
BiPar Sciences
BRISBANE, Kalifornien und PARIS, 20. Mai 2009 (GLOBE NEWSWIRE) -- Die
Ergebnisse der Phase II einer klinischen Studie von BiPar Science - einem
Tochterunternehmen im Besitz von sanofi-aventis - über ...
BiPar Sciences
BSI-201 Phase II Data in Metastatic Triple-Negative Breast Cancer Featured At
ASCO Press Briefing; Study Results Will be Released On Sunday, May 31, 2009, At
8:30 a.m. EDT (Orlando, FL) ...
BiPar Sciences
Les données de phase II du BSI-201 dans le cancer du sein métastatique triple
négatif seront présentées lors d'une conférence de presse officielle de l'ASCO
et intégrées au programme de formation « ...
BiPar Sciences
BRISBANE, Calif. and PARIS, May 18, 2009 (GLOBE NEWSWIRE) -- Results from a Phase II clinical trial of BiPar Sciences' -- a wholly-owned sanofi-aventis subsidiary -- lead PARP inhibitor, BSI-201, will ...
BiPar Sciences
BRISBANE, Calif. and PARIS, April 15, 2009 (GLOBE NEWSWIRE) -- Sanofi-aventis (EURONEXT:SAN) (NYSE:SNY) announced today that it has signed a binding agreement for the acquisition of BiPar Sciences, ...
BiPar Sciences
BRISBANE, Calif., Feb. 3, 2009 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that President ...
BiPar Sciences
BRISBANE, Calif., Jan. 12, 2009 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today it has raised ...
BiPar Sciences
BRISBANE, Calif., Jan. 7, 2009 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that Hoyoung ...
Showing 1-10 of about 16 articles.
